Fig. 5

HRD score and molecular feature analysis of Cohort III. A The distribution of HRD scores in each BRCA status is shown by the histogram plot labeled by different colors as shown in the legend. B The HRD scores of each cancer type are shown by the dot/boxplot where BRCA-status are labeled by different colors as shown in the legend. C The HRD scores of samples with pathogenic BRCA1/2 mutations (both deficient and monoallelic pathogenic samples) are shown by the dot/boxplot and classified into somatic pathogenicity and germline pathogenicity. D The proportion of BRCA-intact patients with gene deficiency in the HRR pathway are shown in the bar plot and colored based on HRD positivity. The p-values of pan-cancer (all BRCA-intact patients in Cohort III), breast, and ovarian cancer patients are shown. E The concurrent mutation analysis shows the significantly differently enriched gene alterations in HRD-positive and HRD-negative ovarian patients. *, p < 0.05; **, p < 0.01; ***, p < 0.001